

Jaime H Vera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2952675/publications.pdf>

Version: 2024-02-01

80
papers

1,320
citations

394421

19
h-index

434195

31
g-index

86
all docs

86
docs citations

86
times ranked

1926
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroinflammation in treated HIV-positive individuals. <i>Neurology</i> , 2016, 86, 1425-1432.	1.1	136
2	Cognitive Impairment in people living with HIV in the ART era: A Review. <i>British Medical Bulletin</i> , 2018, 127, 55-68.	6.9	102
3	Defining cognitive impairment in people-living-with-HIV: the POPPY study. <i>BMC Infectious Diseases</i> , 2016, 16, 617.	2.9	61
4	Neurosyphilis in patients with HIV. <i>Practical Neurology</i> , 2018, 18, 211-218.	1.1	52
5	Global phylogeny of <i>Treponema pallidum</i> lineages reveals recent expansion and spread of contemporary syphilis. <i>Nature Microbiology</i> , 2021, 6, 1549-1560.	13.3	51
6	Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition. <i>Clinical Infectious Diseases</i> , 2019, 68, 87-95.	5.8	49
7	Pain in people living with HIV and its association with healthcare resource use, well being and functional status. <i>Aids</i> , 2018, 32, 2697-2706.	2.2	47
8	Polypharmacy and Drug-drug Interactions in Older and Younger People Living with HIV: The POPPY Study. <i>Antiviral Therapy</i> , 2019, 24, 193-201.	1.0	44
9	Patterns of Co-occurring Comorbidities in People Living With HIV. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy272.	0.9	35
10	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	5.8	34
11	Cohort profile: The Pharmacokinetic and clinical Observations in People over fifty (POPPY) study. <i>International Journal of Epidemiology</i> , 2018, 47, 1391-1392e.	1.9	33
12	Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor. <i>Oncogene</i> , 2006, 25, 260-270.	5.9	29
13	Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1642-1647.	3.0	29
14	Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls. <i>HIV Medicine</i> , 2019, 20, 274-285.	2.2	28
15	Barriers to HIV care and adherence for young people living with HIV in Zambia and mHealth. <i>MHealth</i> , 2019, 5, 45-45.	1.6	26
16	Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV. <i>HIV Medicine</i> , 2017, 18, 363-369.	2.2	24
17	Physical activity and quality of life in people living with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 589-598.	1.2	24
18	PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 895-902.	6.4	22

#	ARTICLE	IF	CITATIONS
19	Assessment and Management of HIV-Associated Cognitive Impairment: Experience from a Multidisciplinary Memory Service for People Living with HIV. <i>Brain Sciences</i> , 2019, 9, 37.	2.3	22
20	Quality of life in people living with HIV-associated neurocognitive disorder: A scoping review study. <i>PLoS ONE</i> , 2021, 16, e0251944.	2.5	21
21	Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa561.	0.9	20
22	Evaluation of a Combined HIV and Geriatrics Clinic for Older People Living with HIV: The Silver Clinic in Brighton, UK. <i>Geriatrics (Switzerland)</i> , 2020, 5, 81.	1.7	19
23	Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. <i>Aids</i> , 2019, 33, 1871-1880.	2.2	18
24	Atherosclerosis is Evident in Treated HIV-Infected Subjects With Low Cardiovascular Risk by Carotid Cardiovascular Magnetic Resonance. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 514-521.	2.1	16
25	AIDSImpact special issue “broadening the lens: recommendations from rehabilitation in chronic disease to advance healthy ageing with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 65-73.	1.2	16
26	Neuroinflammation in HIV-associated depression: evidence and future perspectives. <i>Molecular Psychiatry</i> , 2022, 27, 3619-3632.	7.9	16
27	Acceptability and feasibility of using digital vending machines to deliver HIV self-tests to men who have sex with men. <i>Sexually Transmitted Infections</i> , 2019, 95, 557-561.	1.9	15
28	Level of agreement between frequently used cardiovascular risk calculators in people living with HIV. <i>HIV Medicine</i> , 2019, 20, 347-352.	2.2	14
29	Strengths and Challenges of Various Models of Geriatric Consultation for Older Adults Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 74, 1101-1106.	5.8	14
30	Long COVID and episodic disability: advancing the conceptualisation, measurement and knowledge of episodic disability among people living with Long COVID “ protocol for a mixed-methods study. <i>BMJ Open</i> , 2022, 12, e060826.	1.9	13
31	Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy. <i>HIV Clinical Trials</i> , 2012, 13, 222-227.	2.0	12
32	Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1348-1353.	3.0	12
33	Nanoflow-Nanospray Mass Spectrometry Metabolomics Reveals Disruption of the Urinary Metabolite Profiles of HIV-Positive Patients on Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e45-e53.	2.1	12
34	Preservation of basophils in dapsone-induced agranulocytosis suggests a possible pathogenetic role for leucocyte peroxidases. <i>International Journal of Laboratory Hematology</i> , 2009, 31, 245-247.	1.3	10
35	Acute renal failure due to immune reconstitution inflammatory interstitial nephritis in an HIV-positive patient. <i>Aids</i> , 2010, 24, 1788-1790.	2.2	10
36	HIV and systemic lupus erythematosus: the clinical and diagnostic dilemmas of having dual diagnosis. <i>International Journal of STD and AIDS</i> , 2010, 21, 845-846.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Can antiretroviral therapy prevent HIV-associated cognitive disorders?. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 11-16.	3.8	10
38	The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. <i>HIV Clinical Trials</i> , 2015, 16, 39-42.	2.0	10
39	Sleep health and cognitive function among people with and without HIV: the use of different machine learning approaches. <i>Sleep</i> , 2021, 44, .	1.1	10
40	Can I have the strength to get through this using my past experiences with HIV? findings from a mixed-method survey of health outcomes, service accessibility, and psychosocial wellbeing among people living with HIV during the Covid-19 pandemic. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-7.	1.2	10
41	The predictors of pain extent in people living with HIV. <i>Aids</i> , 2020, 34, 2071-2079.	2.2	9
42	Changes in functional connectivity in people with HIV switching antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2020, 26, 754-763.	2.1	9
43	Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals. <i>Aids</i> , 2021, 35, 1051-1060.	2.2	9
44	Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART. <i>Brain Sciences</i> , 2019, 9, 195.	2.3	8
45	Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals. <i>International Journal of STD and AIDS</i> , 2019, 30, 440-446.	1.1	8
46	High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men. <i>HIV Medicine</i> , 2019, 20, 131-136.	2.2	8
47	Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross-sectional analysis. <i>HIV Medicine</i> , 2020, 21, 441-452.	2.2	8
48	Surveying testing preferences in Black, Latin American, and other minorities for the co-design of digital vending machines for HIV self-testing. <i>International Journal of STD and AIDS</i> , 2020, 31, 158-165.	1.1	8
49	Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 199-205.	2.1	7
50	Impact of musculoskeletal symptoms on physical functioning and quality of life among treated people with HIV in high and low resource settings: A case study of the UK and Zambia. <i>PLoS ONE</i> , 2019, 14, e0216787.	2.5	7
51	Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes. <i>Aids</i> , 2020, 34, 1795-1800.	2.2	7
52	Respiratory symptoms and chronic bronchitis in people with and without HIV infection. <i>HIV Medicine</i> , 2021, 22, 11-21.	2.2	7
53	A fog that impacts everything: a qualitative study of health-related quality of life in people living with HIV who have cognitive impairment. <i>Quality of Life Research</i> , 2022, 31, 3019-3030.	3.1	7
54	Transient bone marrow oedema syndrome in an HIV-infected patient on highly active antiretroviral therapy. <i>International Journal of STD and AIDS</i> , 2012, 23, 213-215.	1.1	6

#	ARTICLE	IF	CITATIONS
55	HIV self-tests for men who have sex with men, accessed via a digital vending machine: a qualitative study of acceptability. <i>International Journal of STD and AIDS</i> , 2020, 31, 420-425.	1.1	6
56	Clinical Utility of 12 -Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 826-833.	2.1	5
57	Disability and self-care living strategies among adults living with HIV during the COVID-19 pandemic. <i>AIDS Research and Therapy</i> , 2021, 18, 87.	1.7	5
58	The impact of COVID-19 on HIV testing in the UK's first Fast-Track HIV city. <i>HIV Medicine</i> , 2022, 23, 790-796.	2.2	5
59	Ophthalmoplegia and Slurred Speech in an Intravenous Drug User. <i>PLoS Medicine</i> , 2006, 3, e453.	8.4	4
60	Monitoring of older HIV-positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative. <i>HIV Medicine</i> , 2020, 21, 409-417.	2.2	4
61	Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. <i>PLoS ONE</i> , 2021, 16, e0253861.	2.5	3
62	The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. <i>Aids</i> , 2013, 27, 484-485.	2.2	2
63	Sporadic CJD in association with HIV. <i>Journal of Neurology</i> , 2019, 266, 253-257.	3.6	2
64	Structured medicines reviews in HIV outpatients: a feasibility study (The MOR Study). <i>HIV Medicine</i> , 2021, , .	2.2	2
65	Point-of-care testing for sexually transmitted infections in low- and middle-income countries: a scoping review protocol. <i>JB Evidence Synthesis</i> , 2021, 19, 155-162.	1.3	2
66	Clinical use of brain magnetic resonance imaging for neurological symptoms in people living with HIV. <i>HIV Medicine</i> , 2018, 19, e66.	2.2	1
67	Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV. <i>Aids</i> , 2020, 34, 790-793.	2.2	1
68	Does duration of HIV infection substitute for age as a risk factor for amyloid deposition?. <i>Aids</i> , 2021, 35, 1501-1502.	2.2	1
69	Correlation between computerised and standard cognitive testing in people with HIV and HIV-negative individuals. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1296-1307.	1.2	1
70	Evaluation of kidney function among people living with HIV initiating antiretroviral therapy in Zambia. <i>PLOS Global Public Health</i> , 2022, 2, e0000124.	1.6	1
71	Increasing access to HIV testing for men who have sex with men in Japan using digital vending machine technology. <i>International Journal of STD and AIDS</i> , 2022, 33, 680-686.	1.1	1
72	Highlights from the Conference on Retroviruses and Opportunistic Infections 2016. <i>Journal of Virus Eradication</i> , 2016, 2, 124-130.	0.5	0

#	ARTICLE	IF	CITATIONS
73	The management of comorbidities in older people living with <scp>HIV</scp> in England: a cross sectional survey. HIV Medicine, 2017, 18, 534-535.	2.2	0
74	P3.129â€¦How can we use phylogenetics to facilitate clinical case finding and partner notification in hiv: lessons from a systematic review of its use in stigmatised infectious diseases. , 2017, , .		0
75	Global sexual health education: STIF in Zambia. Sexually Transmitted Infections, 2018, 94, 2-2.	1.9	0
76	Anal cancer screening in the UK: serial cross-sectional surveys on attitudes and practices. Sexually Transmitted Infections, 2021, 97, 394-394.	1.9	0
77	O17.5â€¦Blood borne viruses screening (BBVS) for temporarily housed rough sleepers in Brighton & Hove during the Covid-19 pandemic. , 2021, , .		0
78	Current screening for HIV. BMJ: British Medical Journal, 2009, 338, b1500-b1500.	2.3	0
79	Highlights from the Conference on Retroviruses and Opportunistic Infections 2016: 22-25 February 2016, Boston, Massachusetts, USA. Journal of Virus Eradication, 2016, 2, 124-30.	0.5	0
80	Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial. HIV Research and Clinical Practice, 2021, , 1-9.	1.1	0